



30 August 2022

Dear Healthcare Professional,

Re: Status update for supply of MINIRIN® Nasal Spray and Nasal Drops:

- **MINIRIN® Nasal Spray (desmopressin acetate 10 microgram/actuation) AUST R 59320**
- **MINIRIN® Nasal Drops (desmopressin acetate 100 micrograms/mL) AUST R 16828**

Following our previous communications regarding the interruption in supply of MINIRIN® Nasal Spray and MINIRIN® Nasal Drops we now are writing to provide further information on the supply situation. Currently there is no stock available for MINIRIN® Nasal Spray and MINIRIN® Nasal Drops.

The production of MINIRIN® Nasal Drops 100 micrograms/mL (0.1 mg/mL) was put on hold in July 2020 due to the detection of a quality issue linked to the primary packaging material. Ferring has no immediate or viable alternative to replace this component.

Consequently, Ferring has decided to discontinue MINIRIN® Nasal Drops 100 micrograms/mL (0.1 mg/mL).

We previously also advised that the production of MINIRIN® Nasal Spray (10 micrograms/actuation) was put on hold because of a manufacturing issue. Please be advised that the production problems for MINIRIN® Nasal Spray are being addressed and at this stage manufacturing is not anticipated to resume before mid-2023. A process for regulatory review and approval will follow, prior to arranging local supply to Australia which is currently expected mid-2024.

Any patients or caregivers with concerns should immediately contact their treating physician for advice about treatment options. The Therapeutic Goods Administration has been notified of this medicines shortage and provides advice on accessing medicines during a shortage on their website:

<https://www.tga.gov.au/accessing-medicines-during-shortage>

The following desmopressin formulations from Ferring are **not** affected by a medicines shortage and are available immediately from pharmacies:

Alternative desmopressin formulation	Approved Indication and PBS status		
	CDI [^]	PNE [^]	RCCT [^]
MINIRIN® (desmopressin acetate) tablets	Indicated PBS Authority	Indicated PBS Authority	
MINIRIN® Melt (desmopressin) sublingual	Indicated Non- PBS‡	Indicated PBS Authority	
MINIRIN® (desmopressin acetate) injection ampoule*	Indicated Non- PBS‡		Indicated Non- PBS‡

*Suitable for patients in an institutional setting where continuous medical care is provided.

† PBS Information: Authority required (STREAMLINED). Refer to PBS Schedule for full authority information.

‡ PBS Information: This product is not listed on the PBS for this indication.

[^] CDI: cranial diabetes insipidus; PNE: primary nocturnal enuresis; RCCT: renal concentrating capacity test

Information on appropriate dosing for these indications are included in the approved product information, available at www.ferring.com.au/products/.

Ferring sincerely regrets any inconvenience caused to you and your patients. If you have any clinical concerns for your patients or if you wish to report any adverse events related to MINIRIN®, please contact our Medical Information team on 1800 337 746 between 9.00 am - 5.00 pm (Australian Eastern Time), Monday to Friday or email at AU.medinfo@fering.com.

Yours faithfully



Hardus van Vuuren
General Manager



Romano Fois
Medical Director